PHAT - Phathom Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
35.31
-0.74 (-2.05%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close36.05
Open36.63
Bid17.00 x 1000
Ask40.00 x 900
Day's Range34.99 - 38.69
52 Week Range18.51 - 47.84
Volume78,214
Avg. Volume158,475
Market Cap866.031M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-23.02
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est34.67
  • PR Newswire

    Frazier Healthcare Partners Closes Oversubscribed $617 Million Life Sciences Fund

    Frazier Healthcare Partners announced today the closing of Frazier Life Sciences X, L.P., exceeding its target and closing on more than $617 million in capital commitments in an oversubscribed fundraise. Investing in life sciences has been a core strategy since the firm's inception 29 years ago, and Frazier Life Sciences X marks the third dedicated Life Sciences fund, bringing the firm's total committed capital raised since inception to nearly $4.8 billion.

  • Business Wire

    Phathom Pharmaceuticals Appoints Martin J. Gilligan as Chief Commercial Officer

    Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced the appointment of Martin J. Gilligan as Chief Commercial Officer. Mr. Gilligan most recently was Corporate Vice President at Celgene Corporation, where he led marketing, market access and business development for Celgene’s Inflammation and Immunology Franchise. He held key leadership roles in the launch and growth of OTEZLA® through its sale to Amgen for $13.4 billion.

  • Business Wire

    Phathom Pharmaceuticals Announces Initiation of Pivotal Phase 3 Clinical Trial for Vonoprazan in Helicobacter Pylori (H. pylori) Infection

    Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the initiation of PHALCON-HP. In this pivotal Phase 3 clinical trial, clinicians will evaluate vonoprazan in combination with amoxicillin (vonoprazan dual therapy) and vonoprazan in combination with amoxicillin and clarithromycin (vonoprazan triple therapy) for the successful eradication of H. pylori infection. With the initiation of PHALCON-HP, vonoprazan is now being evaluated in two pivotal trials to support regulatory submissions in two different disease areas in the United States and Europe. Earlier this month, the company initiated PHALCON-EE, a pivotal trial evaluating vonoprazan for both the healing and maintenance of healing of erosive esophagitis as well as the relief of heartburn. Topline data from both PHALCON-HP and PHALCON-EE are expected in 2021.

  • Business Wire

    Phathom Pharmaceuticals Announces Initiation of Pivotal Phase 3 Clinical Trial for Vonoprazan in Erosive Esophagitis

    Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the initiation of PHALCON-EE, the Company’s pivotal Phase 3 clinical trial of vonoprazan for both the healing and maintenance of healing of erosive esophagitis (EE) as well as the relief of heartburn. PHALCON-EE is a randomized, double-blind, two-phase, multicenter Phase 3 trial that is planned to enroll approximately 1,000 patients with EE in the U.S. and Europe. The first phase of the trial will evaluate the efficacy and safety of vonoprazan 20 mg administered once-daily (QD) compared to lansoprazole 30 mg QD for the healing of EE for up to eight weeks.

  • Business Wire

    Phathom Pharmaceuticals Expands Leadership Team and Announces Board Transition

    Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today multiple executive appointments. As previously announced as part of the Company’s succession plan, Terrie Curran, former President of the Global Inflammation and Immunology (I&I) Franchise at Celgene, now joins Phathom as Chief Executive Officer.

  • Business Wire

    Phathom Pharmaceuticals to Present at Evercore ISI 2019 HealthCONx Conference

    Phathom Pharmaceuticals, Inc. , a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that Azmi Nabulsi, M.D., Chief Operating Officer, will present at the Evercore 2019 HealthCONx Conference on Tuesday, December 3 at 1:35 p.m.

  • TEST Business Wire Releases

    Phathom Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today its results for the third quarter ended September 30, 2019 and provided an update on recent corporate developments.

  • Business Wire

    Phathom Pharmaceuticals to Present at Jefferies 2019 London Healthcare Conference

    Phathom Pharmaceuticals, Inc. , a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that David Socks, President and CEO, will present at the Jefferies 2019 London Healthcare Conference on Wednesday, November 20 at 10:40 a.m.

  • Business Wire

    Phathom Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    Phathom Pharmaceuticals, Inc. , a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the closing of its previously announced initial public offering of 10,997,630 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 1,434,473 additional shares, ...

  • Business Wire

    Phathom Pharmaceuticals Announces Pricing of Initial Public Offering

    Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that it has priced its initial public offering of 9,563,157 shares of its common stock at a public offering price of $19.00 per share. The gross proceeds to Phathom, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $181.7 million. All of the common stock is being offered by Phathom.